TP53 and hepatocellular carcinoma: In particular, it was observed that HCC patients in the high ASF1B group had a significantly higher frequency of TP53 and RB1 mutation, which are typical tumor suppressors, and their mutation leads to tumorigenesis and progression in HCC (Buendia, 2000; Khemlina et al., 2017).